|
Lilly’s Novel Alzheimer’s Disease Drug on Target, Diabetes Drug Gains Approval
Eli Lilly’s experimental Alzheimer’s disease treatment solanezumab is moving forward in separate Phase III trials after clearing a planned analysis by a data monitoring committee.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives